Abstract:Osteoporosis is a progressive systemic skeletal disease, in which the equilibrium of bone resorption and bone formation is disturbed. The drugs for osteoporosis can be divided into two categories according to their predominant effects: antiresorptive drugs and anabolic drugs. Antiresorptive drugs are designed to inhibit bone resorption and anabolic drugs are aiming to stimulate bone formation. On the other hand, most antiresorptive drugs usually decrease anabolic activities and reduce bone formation, while anabolic drugs can unintendedly increase bone resorption. Furthermore, both types of drugs show no preferential distribution in bone and can locate generally in the areas of both bone formation and bone resorption. Consequently, the non-specific interaction of these drugs with non-targeting area and cells can lead to a compromised efficacy. Combined therapies of antiresorptive and anabolic drugs do not necessarily yield superiority when compared to monotherapy. Here, basing on the targeting cells of these two kinds of drugs and the spatial distribution of osteoblasts and osteoclasts, we propose a novel drug delivery system of bi-directionally selective targeting in order to facilitate the efficacy of antiresorptive and anabolic drugs in combined therapy. In the system, an antiresorptive drug will be linked with a peptide of the eight repeating sequences of aspartate--(Asp)8 that can preferentially guide the drugs to bone resorption zone; while an anabolic drug linked with a peptide of six repeats of the sequence aspartate, serine, serine--(Asp-Ser-Ser)6 that can favorably guide the drugs to bone formation zone. The novel delivery system will improve the specific interaction between the drugs and their targeting cells. Furthermore, the system will reduce the non-specific interaction of the anabolic and antiresorptive drugs with their respective non-targeting cells, which will maximally reduce their side-effects. Therefore, we postulate that the new bone targeting drug delivery system will be a blessing for osteoporotic patients.

Bone-Targeted Supramolecular Nanoagonist Assembled by Accurate Ratiometric Herbal-Derived Therapeutics for Osteoporosis Reversal.

Prussian Blue Nanozyme Normalizes Microenvironment to Delay Osteoporosis

Research and Application of Target Therapy for Osteoporosis

A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Fluffy hybrid nanoadjuvants for reversing the imbalance of osteoclastic and osteogenic niches in osteoporosis

Bone-targeting Cell Membrane-Engineered CaCO3-based Nanoparticles Restore Local Bone Homeostasis for Microenvironment-Responsive Osteoporosis Treatment

Reversing the Imbalance in Bone Homeostasis Via Sustained Release of SIRT-1 Agonist to Promote Bone Healing under Osteoporotic Condition

Bone-targeting cell membrane-engineered CaCO 3 -based nanoparticles restore local bone homeostasis for microenvironment-responsive osteoporosis treatment

Bone-Targeted Biomimetic Nanogels Re-Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis

Smart osteoclasts targeted nanomedicine based on amorphous CaCO3 for effective osteoporosis reversal

Bone-targeted Bioengineered Bacterial Extracellular Vesicles Delivering Sirna to Ameliorate Osteoporosis

Novel one-pot strategy for fabrication of a pH-Responsive bone-targeted drug self-frame delivery system for treatment of osteoporosis

Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment

The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis

Inflammatory microenvironment regulation and osteogenesis promotion by bone-targeting calcium and magnesium repletion nanoplatform for osteoporosis therapy

Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis

A Bone-Resorption Surface-Targeting Nanoparticle to Deliver Anti-Mir214 for Osteoporosis Therapy.

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis

Acid Neutralization and Immune Regulation by Calcium–Aluminum-Layered Double Hydroxide for Osteoporosis Reversion

Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?

Attenuating osteoarthritis by a high efficient anti-bone resorption injectable pH-responsive bisphosphonate-conjugated nano-apatite system